Intelligence Platform

Patents

Browse 376 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 8664193

Compositions and methods for inhibiting expression of factor VII gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8614198

Hepatitis C dsRNA effector molecules, expression constructs, compositions, and methods of

Alnylam Pharmaceuticals, Inc. · Granted Tue Dec 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8598139

Lipid formulated dsRNA targeting the PCSK9 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Dec 03 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8598333

SiRNA silencing of genes expressed in cancer

Alnylam Pharmaceuticals, Inc. · Granted Tue Dec 03 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8592570

Compositions and methods for inhibiting expression of an RNA from West Nile virus

Alnylam Pharmaceuticals, Inc. · Granted Tue Nov 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8592571

RNAi modulation of APOB and uses thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Nov 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8575327

Conserved HBV and HCV sequences useful for gene silencing

Alnylam Pharmaceuticals, Inc. · Granted Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8546554

Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gen

Alnylam Pharmaceuticals, Inc. · Granted Tue Oct 01 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8546143

Compositions and methods for inhibiting expression of a target gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Oct 01 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8507661

Modified iRNA agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 13 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8507663

Compositions and methods for inhibiting expression of CD274/PD-L1 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 13 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8507455

Folate conjugates

Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 13 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8470988

Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety

Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 25 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8470799

Compositions and methods for inhibiting expression of the HAMP gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 25 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8450467

Carbohydrate conjugates as delivery agents for oligonucleotides

Alnylam Pharmaceuticals, Inc. · Granted Tue May 28 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 23 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8445665

Therapeutic compositions

Alnylam Pharmaceuticals, Inc. · Granted Tue May 21 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 16 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8420799

Therapeutic compositions

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 16 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8410261

Compositions and methods for inhibiting expression of a gene from the JC virus

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 02 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8410073

Methods and compositions for prevention or treatment of RSV infection

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 02 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8404862

Ligand-conjugated monomers

Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8350021

Conserved HBV and HCV sequences useful for gene silencing

Alnylam Pharmaceuticals, Inc. · Granted Tue Jan 08 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 03 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8344125

Modified iRNA agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Jan 01 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8344126

Compositions and methods for inhibiting expression of XBP-1 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Jan 01 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8334273

Compositions and methods for inhibiting expression of factor VII gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Dec 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted